Overview1,2
Elritercept is designed to bind to and block downstream signaling of select TGF-β superfamily ligands, including Activin A/B and GDF8/111,2
Mechanism of Action1,2
- Elritercept binds to Activin A/B and GDF8/11, thereby preventing their binding to Activin/TGF-β pathway receptors and inhibiting downstream signaling, resulting in rebalanced pathways1,2
Clinical Trials
Study Name
A Study of KER-050 to Treat Anemia Due to Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes
CT.GOV ID
NCT04419649
Phase
Phase 2
Status
Recruiting
View on ClinicalTrials.govStudy Name
The Efficacy and Safety of Elritercept in Adult Participants With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) With Anemia (RENEW)
CT.GOV ID
NCT06499285
Phase
Phase 3
Status
Recruiting
Study Name
Study to Evaluate KER-050 as a Monotherapy or in Combination With Ruxolitinib in Myelofibrosis
CT.GOV ID
NCT05037760
Phase
Phase 2
Status
Recruiting
Study Name
Randomized, Double-Blind, Placebo-Controlled, Two-Part, Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Effects of KER-050 Administered to Healthy, Postmenopausal Women.
CT.GOV ID
NCT05037760
Phase
Phase 1
Status
Completed
References
1. Lachey J, et al. Blood Adv. 2025;9:193–200.
2. Verma A, et al. J Clin Invest. 2020;130:582–589.
Didn't find what you are looking for? Contact Us
Med Info!
Takeda Live Chat
Confirm Exit?
On exiting, all chat history will be cleared
